Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

.240 billion, an increase of 8 percent compared with the same period in 2010. Reported net income and earnings per share were $3.489 billion and $3.13, respectively. Net income and earnings per share, on a non-GAAP basis, were $3.945 billion and $3.54, respectively.

For purposes of non-GAAP reporting, items totaling $.41 per share for the first nine months of 2011 and $.10 per share for the first nine months of 2010 have been excluded. For further detail, see the reconciliation below as well as the footnotes to the non-GAAP income statement later in this press release. Year-to-date

% Growth20112010Earnings per share (reported)$3.13$3.53(11)%In-process research and development charges
associated with Boehringer Ingelheim
collaboration (2011) and Acrux licensing
agreement (2010)

.23.03Restructuring charges

.18.07Earnings per share (non-GAAP)  $3.54$3.63(2)%U.S. Health Care Reform Impact

U.S. health care reform reduced earnings per share in the third quarters of 2011 and 2010 by approximately $.13 and $.02 per share, respectively, on both a reported and non-GAAP basis. U.S. health care reform reduced earnings per share in the first nine months of 2011 and 2010 by approximately $.35 and $.19 per share, respectively, on both a reported and non-GAAP basis. For the first nine months of 2011, U.S. health care reform reduced revenue by approximately $330 million due to higher rebates and subsidies, and increased administrative expenses by approximately $135 million related to the mandatory pharmaceutical manufacturers fee. For the first nine months of 2010, U.S. health care reform reduced revenue by approximately $160 million due to higher rebates, and increased tax expense by $85 million due to the imposition of tax on the prescription drug subsidy of the company's retiree health plan.Revenue Highlights – Reported(Dollars in millions)Third Quarter

% Change
Over/(Under)Year-to-Date

% Change
Over/(U
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Indien, August 1, 2014 ... Inc. gaben heute bekannt, vor kurzem für ... zur Schmerzbehandlung nach chirurgischen Eingriffen eine kommerzielle ... der Europäischen Union und weiterer europäischer Länder ... und mit Ropivacain gefüllte OneDose ReadyfusOR später ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
(Date:7/31/2014)... 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® Insulin Pump, today reported its financial results for ... comparing the second quarter of 2014 to the same period ... million from $5.5 million , t:slim Pump shipments grew ... In comparing six months ended June 30, 2014 to the ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4
... , NEW YORK, Dec. 8 ... is available in its catalogue: , South Korean ... , http://www.reportlinker.com/p0166833/South-Korean-Market-for-Dental-Implants-and-Final-Abutments-2009.html , In 2008, the ... was the largest in the Asia-Pacific region. The intense ...
... , ... that a new market research report is available in ... European Market Analysis , http://www.reportlinker.com/p0164273/Radiopharmaceuticals---A-US-and-European-Market-Analysis.html , ... heightened interest in therapeutic efficiency, acceptance and utilization of ...
Cached Medicine Technology:Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10
(Date:8/1/2014)... (PRWEB) August 01, 2014 The European gas ... Europe with analysis and forecast of revenue. The gas chromatography ... 2013, and is estimated to grow to around $247.6 million ... 2018. , Browse through the TOC of the European gas ... analysis provided. This also provides a glimpse of the segmentation ...
(Date:8/1/2014)... August 01, 2014 Recently, Agebc.com, a renowned ... of prom dresses . As a matter of fact, ... top experts. Aside from that, all of them are offered ... has a huge selection of graceful products for clients who ... sale will not last for a long period of time. ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted to ... Curran, PhD, of the University of Southern California as ... Award. , This distinguished honor is given for outstanding ... research. It was established in 1986 to honor Nathan ... in gerontological research at the National Institutes of Health. ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new ... clients who have high cholesterol levels. , Clients ... qualify for no medical exam life insurance. These plans ... medical check-ups. , Since there are no medical examinations ... qualify in just a few minutes. However, this convenience ...
(Date:8/1/2014)... 01, 2014 Frontier Nursing University has ... Services Administration’s Advanced Education Nursing Traineeship (AENT) program ... direct support to 280 students over the grant period. ... is to increase the number of advanced education nurses ... faculty to address the nurse faculty shortage that inhibits ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cheap Prom Dresses At The Renowned Dresses Manufacturer and Retailer Agebc.com 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2
... a new, targeted therapy for metastatic urothelial cancer has ... 35th Congress of the European Society for Medical Oncology ... tissue lining the inner surfaces of the bladder and ... metastatic disease, median survival is approximately 12-15 months and ...
... diagnosed with bone cancer could benefit from better treatment in ... Nottingham. The Bone Cancer Research Trust launches Bone Cancer ... the University which is testing a theory that ,friendly bacteria, ... at the School of Clinical Sciences, Division of Pre-Clinical Oncology ...
... cardiovascular surgeons and cardiologists from 25 countries are scheduled ... two-day surgical congress focused on the Ross Procedure. ... will feature the presentation of much new data about ... the world,s elite cardiovascular surgeons and cardiologists regarding survival, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... be at higher risk for stroke even if they don,t ... attention to people who show signs of insulin resistance -- ... clear glucose from the bloodstream -- may be helpful in ...
... cancer can lead some people to wonder if their risk ... than 85,000 postmenopausal women observed that regular physical activity, maintaining ... risk for women with, and without a family history of ... published online Oct. 12, 2010, by the journal Breast ...
... artery that supplies blood to the brain, carotid artery ... an increased risk of both short- and long-term adverse ... to a meta-analysis of previously published studies that was ... 2011 print issue of Archives of Neurology , ...
Cached Medicine News:Health News:Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer 2Health News:Hope for a new treatment for bone cancer 2Health News:The Ross Summit to focus on new survival data, technique refinement and availability 2Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:Breast-healthy lifestyle worthwhile, URMC study confirms 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: